There are other examples in cancer therapeutics such as the combination of BRAF and EGFR inhibitors which effectually influence AKT, MEK and ERK signaling, suggested for colon cancer patients with BRAF mutations19. In the mentioned cases, combinatorial therapeutics resulted in more effective impacts compared to monotherapies due to the synergistic effects on different functionalities of the cells. The gene discussed is BRAF; the disease is malignant colon neoplasm.